{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(9)"],"submitter":["Alsowaida YS"],"pubmed_abstract":["<h4>Aim</h4>To evaluate the efficiency of Bayesian modeling software and first-order pharmacokinetic (PK) equations to calculate vancomycin area under the concentration-time curve (AUC) estimations.<h4>Methods</h4>Unblinded, crossover, quasi-experimental study at a tertiary care hospital for patients receiving intravenous vancomycin. Vancomycin AUC monitoring was compared using Bayesian modeling software or first-order PK equations. The primary endpoint was the time taken to estimate the AUC and determine regimen adjustments. Secondary endpoints included the percentage of vancomycin concentrations usable for AUC calculations and acute kidney injury (AKI).<h4>Results</h4>Of the 124 patients screened, 34 patients had usable vancomycin concentrations that led to 44 AUC estimations. Without el"],"journal":["Antibiotics (Basel, Switzerland)"],"pagination":["1239"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9495010"],"repository":["biostudies-literature"],"pubmed_title":["Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study."],"pmcid":["PMC9495010"],"pubmed_authors":["Kovacevic MP","Dionne B","Kubiak DW","Alsowaida YS","Pearson JC"],"additional_accession":[]},"is_claimable":false,"name":"Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study.","description":"<h4>Aim</h4>To evaluate the efficiency of Bayesian modeling software and first-order pharmacokinetic (PK) equations to calculate vancomycin area under the concentration-time curve (AUC) estimations.<h4>Methods</h4>Unblinded, crossover, quasi-experimental study at a tertiary care hospital for patients receiving intravenous vancomycin. Vancomycin AUC monitoring was compared using Bayesian modeling software or first-order PK equations. The primary endpoint was the time taken to estimate the AUC and determine regimen adjustments. Secondary endpoints included the percentage of vancomycin concentrations usable for AUC calculations and acute kidney injury (AKI).<h4>Results</h4>Of the 124 patients screened, 34 patients had usable vancomycin concentrations that led to 44 AUC estimations. Without el","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-03T21:30:37.177Z","creation":"2025-04-03T21:30:37.177Z"},"accession":"S-EPMC9495010","cross_references":{"pubmed":["36140021"],"doi":["10.3390/antibiotics11091239"]}}